Sacubitril/Valsartan Improves Heart and Lung Blood Flow in Patients Awaiting Heart Transplant
Switching to sacubitril/valsartan improved both pulmonary and systemic hemodynamics in advanced heart failure patients on the heart transplant waiting list.
Quick Facts
What This Study Found
Sacubitril/valsartan improved hemodynamic parameters of both pulmonary and systemic circulation compared to conventional ACE inhibitors/ARBs in patients with advanced heart failure awaiting transplantation.
Key Numbers
Retrospective analysis; improved echocardiographic and hemodynamic parameters; reduced NT-proBNP; patients awaiting HTX.
How They Did This
Retrospective analysis comparing echocardiographic, laboratory, and hemodynamic parameters before and after switching to sacubitril/valsartan in advanced heart failure patients awaiting heart transplantation.
Why This Research Matters
Improving hemodynamics while waiting for transplant can reduce complications, improve quality of life, and potentially improve transplant candidacy and outcomes.
The Bigger Picture
Sacubitril/valsartan works partly by preventing the breakdown of natriuretic peptides (via neprilysin inhibition), demonstrating how peptide-pathway modulation can have profound effects on cardiovascular hemodynamics.
What This Study Doesn't Tell Us
Retrospective study design limits causal conclusions; single-center data; no randomized control group; small sample size typical for transplant-waitlist populations.
Questions This Raises
- ?Does sacubitril/valsartan-related hemodynamic improvement translate to better post-transplant outcomes?
- ?Could some patients improve enough on this therapy to be delisted from transplant waiting lists?
Trust & Context
- Key Stat:
- Improved pulmonary and systemic hemodynamics after switching to sacubitril/valsartan
- Evidence Grade:
- Retrospective single-center study; provides useful clinical data but lacks the rigor of a randomized controlled trial.
- Study Age:
- Published in 2025, adding to the evidence for sacubitril/valsartan in the most severe heart failure populations.
- Original Title:
- Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation.
- Published In:
- Journal of clinical medicine, 14(8) (2025)
- Authors:
- Ráduly, Arnold Péter, Saman Kothalawala, Edward, Balogh, László, Majoros, Zsuzsanna, Pólik, Zsófia, Fülöp, László, Győry, Ferenc, Nagy, László, Bódi, Beáta, Kovács, Máté Balázs, Csanádi, Zoltán, Papp, Zoltán, Muk, Balázs, Borbély, Attila
- Database ID:
- RPEP-13342
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What is sacubitril/valsartan?
Sacubitril/valsartan (Entresto) is a combination medication that boosts beneficial natriuretic peptides (by inhibiting the enzyme neprilysin that breaks them down) while blocking harmful angiotensin II signaling. It is a cornerstone treatment for heart failure.
How does this help transplant patients?
By improving blood flow through both the lungs and body, sacubitril/valsartan can stabilize patients during the often lengthy wait for a donor heart, potentially reducing hospitalizations and improving overall condition before surgery.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13342APA
Ráduly, Arnold Péter; Saman Kothalawala, Edward; Balogh, László; Majoros, Zsuzsanna; Pólik, Zsófia; Fülöp, László; Győry, Ferenc; Nagy, László; Bódi, Beáta; Kovács, Máté Balázs; Csanádi, Zoltán; Papp, Zoltán; Muk, Balázs; Borbély, Attila. (2025). Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation.. Journal of clinical medicine, 14(8). https://doi.org/10.3390/jcm14082539
MLA
Ráduly, Arnold Péter, et al. "Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation.." Journal of clinical medicine, 2025. https://doi.org/10.3390/jcm14082539
RethinkPeptides
RethinkPeptides Research Database. "Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulm..." RPEP-13342. Retrieved from https://rethinkpeptides.com/research/raduly-2025-sacubitrilvalsartan-improves-hemodynamic-parameters
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.